🚀 VC round data is live in beta, check it out!
- Public Comps
- Ocugen
Ocugen Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ocugen and similar public comparables like Cormedix, Prime Medicine, Aclaris Therapeutics, Zevra Therapeutics and more.
Ocugen Overview
About Ocugen
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Founded
2000
HQ

Employees
95
Website
Financials (LTM)
EV
$624M
Valuation Multiples
Start free trialOcugen Financials
Ocugen reported last 12-month revenue of $3M.
In the same LTM period, Ocugen generated had net loss of ($69M).
Revenue (LTM)
Ocugen P&L
In the most recent fiscal year, Ocugen reported revenue of $4M and EBITDA of ($60M).
Ocugen is unprofitable as of last fiscal year, with EBITDA margin of (1366%) and net margin of (1537%).
Financial data powered by Morningstar, Inc.
Ocugen Stock Performance
Ocugen has current market cap of $609M, and enterprise value of $624M.
Market Cap Evolution
Ocugen's stock price is $1.80.
Ocugen share price increased by 4.0% in the last 30 days, and by 115.3% in the last year.
Ocugen has an EPS (earnings per share) of $-0.20.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $624M | $609M | 4.0% | 4.0% | -1.1% | 115.3% | $-0.20 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOcugen Valuation Multiples
Ocugen trades at 178.5x EV/Revenue multiple, and (10.4x) EV/EBITDA.
EV / Revenue (LTM)
Ocugen Financial Valuation Multiples
As of May 2, 2026, Ocugen has market cap of $609M and EV of $624M.
Ocugen has a P/E ratio of (8.9x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ocugen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Ocugen Margins & Growth Rates
Ocugen decreased revenue by 62% but net profit grew by 4% in the last fiscal year.
In the most recent fiscal year, Ocugen reported EBITDA margin of (1366%) and net margin of (1537%).
Ocugen Margins
Ocugen Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Ocugen Operational KPIs
Ocugen's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Ocugen Competitors
Ocugen competitors include Cormedix, Prime Medicine, Aclaris Therapeutics, Zevra Therapeutics, Supriya Lifescience, Luzhu Biotech, Sutro Biopharma, TTY Biopharm, Tempo Scan Pacific and Abclon.
Most Ocugen public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.0x | 2.0x | 3.1x | 3.6x | |||
| 119.5x | 58.9x | (2.8x) | (2.9x) | |||
| 67.1x | 77.5x | (7.5x) | — | |||
| 4.4x | 3.9x | 4.7x | (16.3x) | |||
| 8.1x | 6.5x | 20.4x | 19.3x | |||
| — | 17.9x | (27.2x) | (157.1x) | |||
| 4.5x | 5.8x | (3.3x) | (3.3x) | |||
| 2.6x | 2.5x | 7.1x | — | |||
This data is available for Pro users. Sign up to see all Ocugen competitors and their valuation data. Start Free Trial | ||||||
Ocugen Funding History
Before going public, Ocugen raised $14M in total equity funding, across 2 rounds.
Ocugen Funding Rounds
Ocugen M&A Activity
Ocugen has acquired 1 company to date.
Last acquisition by Ocugen was on September 30th 2019. Ocugen acquired Histogenics for undisclosed valuation.
Latest Acquisitions by Ocugen
| Description | Histogenics was a Waltham-headquartered leader in musculoskeletal regenerative medicine focused on cartilage repair. Its NeoCart implant combines autologous cartilage cells with a bovine collagen scaffold for knee defects. The platform integrates tissue engineering and bioadhesives for orthopedic applications. After Phase 3 trials, the company faced challenges and filed for bankruptcy in 2019, with assets acquired by Sobi. |
| HQ Country | |
| HQ City | Boston, MA |
| Deal Date | 30 Sep 2019 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Ocugen acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ocugen
| When was Ocugen founded? | Ocugen was founded in 2000. |
| Where is Ocugen headquartered? | Ocugen is headquartered in United States. |
| How many employees does Ocugen have? | As of today, Ocugen has over 95 employees. |
| Who is the CEO of Ocugen? | Ocugen's CEO is Shankar Musunuri. |
| Is Ocugen publicly listed? | Yes, Ocugen is a public company listed on Nasdaq. |
| What is the stock symbol of Ocugen? | Ocugen trades under OCGN ticker. |
| When did Ocugen go public? | Ocugen went public in 2014. |
| Who are competitors of Ocugen? | Ocugen main competitors include Cormedix, Prime Medicine, Aclaris Therapeutics, Zevra Therapeutics, Supriya Lifescience, Luzhu Biotech, Sutro Biopharma, TTY Biopharm, Tempo Scan Pacific, Abclon. |
| What is the current market cap of Ocugen? | Ocugen's current market cap is $609M. |
| What is the current revenue of Ocugen? | Ocugen's last 12 months revenue is $3M. |
| What is the current revenue growth of Ocugen? | Ocugen revenue growth (NTM/LTM) is 333%. |
| What is the current EV/Revenue multiple of Ocugen? | Current revenue multiple of Ocugen is 178.5x. |
| Is Ocugen profitable? | No, Ocugen is not profitable. |
| What is the current net income of Ocugen? | Ocugen's last 12 months net income is ($69M). |
| How many companies Ocugen has acquired to date? | As of May 2026, Ocugen has acquired 1 company. |
| What was the largest acquisition by Ocugen? | None of the M&A deals Ocugen has completed have disclosed valuations. |
| What companies Ocugen acquired? | Ocugen acquired Histogenics. |
| In how many companies Ocugen has invested to date? | Ocugen hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Ocugen
Lists including Ocugen
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
